The present invention relates to bisbenzofuran-fused 2,8-diaminoindeno[1,2-b]fluorene derivatives and related compounds of formula (1) as materials for organic electroluminescent devices (OLEDs).

The present invention discloses a 5,12-dihydrotetracene derivative and an organic electroluminescence device employing the 5,12-dihydrotetracene derivative as the thermally activated delayed fluorescence host material or the thermally activated delayed fluorescence dopant material in the light emitting layer. The organic electroluminescence device of the present invention exhibits improved performance, such as reduced power consumption and increased current efficiency.

The present invention relates to a process for preparing a partially hydrogenated polyacene, and a novel intermediate used in such process; also the present invention relates to a process for preparing the corresponding conjugated polyacenes.

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.

The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits. ##STR00001##

According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4-epi-feudomycin, which are typical impurities possibly contained in 4-epi-daunorubicin as a starting material, by using an organic acid salt of 4-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.

The present invention is directed to a compound represented by Structural Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

The present invention has the configuration described below for the purpose of providing a photoelectric conversion efficiency element which exhibits high charge mobility, while having high photoelectric conversion efficiency. A photoelectric conversion element which comprises at least one organic layer between a first electrode and a second electrode, and which is characterized in that the organic layer contains a first compound represented by general formula (1) and a second compound that has a maximum value of absorption coefficient of 510.sup.4 cm.sup.1 or more at a wavelength of 400-700 nm.

The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. ##STR00001##